Cancer patients across India should now be paying much less for many of their medicines. From 9 November 2026, a cap on trade margins covering 137 anti-cancer drugs is in force, and companies have already cut the printed prices of more than a thousand formulations. Some medicines now cost a small fraction of what they did last month.
The order comes from the National Pharmaceutical Pricing Authority (NPPA), which works under the Department of Pharmaceuticals. It was notified on 17 October and gave companies time to revise their maximum retail prices (MRPs) before the deadline.
What the government has changed
The NPPA has capped the trade margin on 137 non-scheduled anti-cancer medicines at 30 per cent. Trade margin is the gap between the price a company charges its stockist or distributor and the MRP the patient pays, not counting GST. Under the new rule, a drug sold to a distributor at Rs 70 cannot carry a pre-tax MRP above Rs 100.
The cap covers all strengths and dosage forms, single drugs as well as combinations. Patented medicines are included. Among the drugs named in reports are pembrolizumab, nivolumab, durvalumab, osimertinib, olaparib, ibrutinib, pegfilgrastim and denosumab, several of which are used in immunotherapy and targeted therapy.
How big are the price cuts?
According to data released on 10 November and reported by ETV Bharat, 85 companies had reported revised MRPs for 1,366 product lines of 121 drugs by 9 November. Earlier government figures showed price cuts on 1,031 formulations, with 600 brands cutting prices by more than half. The steepest cut so far is 96.45 per cent.
A few examples from the revised lists:
- Bevacizumab 100 mg (Bryxta, Zydus): down from Rs 25,995 to Rs 3,318
- Abiraterone 250 mg (Abirone): down from Rs 41,250 to Rs 3,218.23
- Palbociclib 125 mg (Palbopro): down from Rs 40,421.33 to Rs 2,720
- Pertuzumab 420 mg (Lupiher 2, Lupin): down from Rs 83,520 to Rs 37,358.35
The government estimates that consumers will save about Rs 3,502 crore a year. This is an official estimate, and the real figure will depend on how many patients buy these brands and whether pharmacies and hospitals actually charge the new prices.
Of the 137 drugs on the list, 10 to 15 are not yet sold in India. The margin cap will apply to them as soon as they are launched.
Why the government used special powers
Most of these medicines are not on the National List of Essential Medicines, so their prices were not directly controlled. Under the Drugs (Prices Control) Order, 2013, companies can raise the MRP of such drugs by up to 10 per cent a year. That rule limits increases but does nothing about prices that are already high.
So the government used Paragraph 19 of the order, which allows it to fix or revise prices in extraordinary circumstances and in the public interest. The list was drawn up on the advice of an expert committee set up by the Directorate General of Health Services.
India has tried this before. In 2019, a pilot capped margins at 30 per cent on 42 anti-cancer drugs, and MRPs of 526 brands fell by up to 90 per cent. The new order is far wider.
The need is growing. Health Ministry figures shared with Parliament put estimated cancer cases at nearly 15.7 lakh in 2025, up from about 14.26 lakh in 2021. For many families, treatment costs run into lakhs of rupees, and medicines make up a large share of the bill.
Rules for companies, chemists and hospitals
Companies must report revised prices to the NPPA, publish them on their websites and inform retailers and hospitals. Drugs that were already priced below the new ceiling cannot be made costlier. Firms that fail to cut prices must deposit the overcharged amount with interest.
Retailers, dealers, hospitals and medical institutions must display the revised price lists prominently, both on their premises and on their websites. State Drug Controllers will monitor compliance, and the government has warned of strict action against chemists and hospital pharmacies that overcharge.
How patients can check prices
If you or a family member is on cancer treatment, a few simple checks can help:
- Compare the price on the pack with the revised list on the NPPA website or the Pharma Sahi Daam mobile app.
- Ask the hospital pharmacy for its displayed price list.
- Keep your prescription and purchase bill. You will need them if you file a complaint.
- Report overcharging through the Pharma Sahi Daam app, the NPPA helpline (1800-11-1255) or the NPPA monitoring email.
Do not change or stop any treatment because of a price difference; talk to your oncologist first.
Reporting based on ETV Bharat, Greater Kashmir, The Public World, Organiser, VOH Network
Featured image: epSos.de, via Wikimedia Commons (CC BY 2.0)

